PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 261 filers reported holding PACIRA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.85 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $621,606 | -2.3% | 15,513 | -0.5% | 0.00% | 0.0% |
| Q1 2023 | $636,513 | +4.7% | 15,597 | -0.9% | 0.00% | 0.0% |
| Q4 2022 | $607,722 | -28.3% | 15,740 | -1.1% | 0.00% | 0.0% |
| Q3 2022 | $847,000 | -2.2% | 15,911 | +7.2% | 0.00% | 0.0% |
| Q2 2022 | $866,000 | -21.3% | 14,840 | +3.0% | 0.00% | -50.0% |
| Q1 2022 | $1,100,000 | -31.0% | 14,414 | -45.6% | 0.00% | 0.0% |
| Q4 2021 | $1,595,000 | -1.2% | 26,508 | -8.0% | 0.00% | 0.0% |
| Q3 2021 | $1,614,000 | +2.5% | 28,825 | +11.1% | 0.00% | 0.0% |
| Q2 2021 | $1,574,000 | +70.7% | 25,936 | +97.2% | 0.00% | 0.0% |
| Q1 2021 | $922,000 | +15.5% | 13,151 | -1.4% | 0.00% | +100.0% |
| Q4 2020 | $798,000 | -1.0% | 13,340 | -0.5% | 0.00% | -50.0% |
| Q3 2020 | $806,000 | -27.9% | 13,408 | -37.1% | 0.00% | -33.3% |
| Q2 2020 | $1,118,000 | +309.5% | 21,305 | +161.1% | 0.00% | +200.0% |
| Q1 2020 | $273,000 | -57.5% | 8,161 | -42.7% | 0.00% | 0.0% |
| Q4 2019 | $642,000 | +10.7% | 14,250 | -5.8% | 0.00% | 0.0% |
| Q3 2019 | $580,000 | -7.8% | 15,124 | +5.3% | 0.00% | -50.0% |
| Q2 2019 | $629,000 | +0.6% | 14,357 | -12.1% | 0.00% | 0.0% |
| Q1 2019 | $625,000 | +8.1% | 16,331 | +21.6% | 0.00% | 0.0% |
| Q4 2018 | $578,000 | -17.8% | 13,427 | -6.1% | 0.00% | 0.0% |
| Q3 2018 | $703,000 | +151.1% | 14,293 | +64.6% | 0.00% | +100.0% |
| Q2 2018 | $280,000 | -7.9% | 8,685 | -10.7% | 0.00% | 0.0% |
| Q1 2018 | $304,000 | -38.5% | 9,724 | -10.3% | 0.00% | -50.0% |
| Q4 2017 | $494,000 | +39.9% | 10,842 | +15.7% | 0.00% | +100.0% |
| Q3 2017 | $353,000 | +27.0% | 9,367 | +158.3% | 0.00% | 0.0% |
| Q4 2015 | $278,000 | -54.3% | 3,626 | -57.8% | 0.00% | -50.0% |
| Q2 2015 | $608,000 | -35.5% | 8,600 | -18.8% | 0.00% | -60.0% |
| Q1 2015 | $942,000 | +10.8% | 10,596 | +10.7% | 0.01% | 0.0% |
| Q4 2014 | $850,000 | -10.2% | 9,574 | -2.0% | 0.01% | -37.5% |
| Q3 2014 | $947,000 | -21.5% | 9,772 | -25.7% | 0.01% | -27.3% |
| Q2 2014 | $1,207,000 | +15.4% | 13,144 | -12.1% | 0.01% | +10.0% |
| Q1 2014 | $1,046,000 | – | 14,948 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |